ResearcherUniversity of MacauActive in the last 2 years

Weimin Zuo

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0002-7744-8132; OpenAlex author ID A5054342681.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Collaborators: 3

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB/PI3K/AKT/mTOR/MYC signaling axis. First author DOI 10.1186/s12964-026-02856-6 ↗
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting m… Co-author DOI 10.1186/s13046-019-1160-9 ↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Hang Fai Kwok · 1 shared paper, 2026
- Paper An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB/PI3K/AKT/mTOR/MYC signaling a… DOI 10.1186/s12964-026-02856-6 ↗
Shuiliang Wang · 1 shared paper, 2019
- Paper Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via indu… DOI 10.1186/s13046-019-1160-9 ↗
Tingting Lin · 1 shared paper, 2019
- Paper Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via indu… DOI 10.1186/s13046-019-1160-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.